American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
The University of California has settled a dispute over the use of a diagnostic tool in graduate research projects.
German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
US biotechnology company Celgene has taken legal action against the registrant of a domain name which allegedly infringes Celgene’s trademarks.
Biopharmaceutical company Sensorion has entered into a research collaboration with French research body Institut Pasteur.
A subsidiary of China-based genome sequencing company BGI has filed a patent infringement suit against a US competitor.
GSK has entered into a settlement agreement with California-based Laclede, ending a trademark infringement dispute between the pair.
The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.
Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.
The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.